Final Results of a Multicenter Phase Ib Single Agent Study with the Novel Anti-CD20 Monoclonal Antibody Ublituximab (TG-1101) in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL).

Drug Category : Array
Conference Category : Array
Lead Author : Cazin B, Ribrag V, et al.
Published Date : 04/06/2013
Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2019/03/EHA2013PosterP111.pdf
Download Text : Download
Popup Confirmation? :
site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
astra-migrate-meta-layouts : set
Scroll to Top